MedTrace Logo

Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers

NCT02751359 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this double-blind, placebo-controlled study is to determine the analgesic effects of cannabidiol (CBD), a chemical constituent found in cannabis that does not have intoxicating effects. The analgesic effects of CBD will be assessed using the Cold-Pressor Test (CPT), a laboratory model of pain which has predictive validity for the clinical use of analgesics.

Conditions

Interventions

DRUG

Cannabidiol

200, 400, or 800 mg Cannabidiol

DRUG

Placebo

0 mg Cannabidiol

Sponsors & Collaborators

Principal Investigators

  • Ziva D Cooper, PhD · New York State Psychiatric Institute / CUMC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-07-31
Completion
2020-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02751359 on ClinicalTrials.gov